This inventor holds 1 USPTO granted patent. Top assignee: Symbiotec Gesellschaft Zur Erforschung Und Entwicklung Auf Dem Gebiet Der Biotechnologic Mbh. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Ladislav Cebecauer: Innovator in Biotechnological Solutions
Introduction
Ladislav Cebecauer is a notable inventor based in Piešťany, Slovakia. He has made significant contributions to the field of biotechnology, particularly in the diagnosis and therapy of systemic lupus erythematosus (SLE). His innovative work has led to the development of peptides that play a crucial role in medical diagnostics and treatment.
Latest Patents
Cebecauer holds a patent for "Peptides for the production of preparations for the diagnosis and therapy of systemic lupus." This patent involves peptides with antigenic or immunogenic determinants derived from autoantibodies found in the body fluids of SLE patients. Specifically, the invention focuses on the C terminus of H1 with the sequence section 187-211 and the N termini of H2B with sequence sections 1-35 and 36-76. These peptides are capable of cross-reactions with anti-histone antibodies. The invention also outlines methods for forming monoclonal antibodies and anti-idiotypical antibodies directed against autoantibodies, enhancing the accuracy of SLE diagnosis and providing a foundation for therapeutic development.
Career Highlights
Cebecauer is associated with Symbiotec Gesellschaft zur Erforschung und Entwicklung auf dem Gebiet der Biotechnologie mbH, where he continues to advance his research in biotechnology. His work has been instrumental in bridging the gap between scientific research and practical medical applications.
Collaborations
Cebecauer has collaborated with notable colleagues such as Michael Zeppezauer and Arno Schönberger. Their combined expertise has contributed to the success of various projects within the biotechnology sector.
Conclusion
Ladislav Cebecauer's innovative contributions to biotechnology, particularly in the diagnosis and treatment of systemic lupus erythematosus, highlight his role as a key figure in the field. His patent and ongoing research continue to pave the way for advancements in medical science.